Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma. O'Rourke K. Cancer 2022;128:1887.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

O'Rourke K. Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma. Cancer 2022;128:1887.
PMID: 35467765